Concepts (47)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 4 | 2011 | 236 | 0.680 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 539 | 0.580 |
Why?
|
| Autoantibodies | 2 | 2010 | 63 | 0.390 |
Why?
|
| Early Detection of Cancer | 2 | 2010 | 100 | 0.380 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 16 | 0.330 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 9 | 0.330 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.330 |
Why?
|
| Algorithms | 3 | 2010 | 305 | 0.160 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 200 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2011 | 1467 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 61 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 5 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2011 | 76 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 11 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 86 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 41 | 0.080 |
Why?
|
| Proteomics | 1 | 2010 | 61 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 243 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 135 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 485 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2009 | 10 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 30 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 50 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 3865 | 0.060 |
Why?
|
| Humans | 5 | 2011 | 23187 | 0.060 |
Why?
|
| Adult | 3 | 2011 | 6959 | 0.060 |
Why?
|
| Aged | 3 | 2011 | 7660 | 0.050 |
Why?
|
| Middle Aged | 3 | 2011 | 7981 | 0.050 |
Why?
|
| Male | 4 | 2011 | 12659 | 0.050 |
Why?
|
| Female | 3 | 2011 | 13142 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2011 | 2943 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 49 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 80 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 15 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 168 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 226 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 228 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 279 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 288 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 353 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 550 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1430 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 578 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 812 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 875 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 2993 | 0.010 |
Why?
|